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Abstract
The human GFAP splice variants GFAPD164 and GFAPDexon6 both result in a GFAP protein isoform with a unique out-of-
frame carboxy-terminus that can be detected by the GFAP
+1 antibody. We previously reported that GFAP
+1 was expressed
in astrocytes and in degenerating neurons in Alzheimer’s disease brains. In this study we aimed at further investigating the
neuronal GFAP
+1 expression and we started by affinity purifying the GFAP
+1 antibody. The purified antibody resulted in a
loss of neuronal GFAP
+1 signal, although other antibodies directed against the amino- and carboxy-terminus of GFAPa still
revealed GFAP-immunopositive neurons, as described before. With an in-depth analysis of a western blot, followed by mass
spectrometry we discovered that the previously detected neuronal GFAP
+1 expression was due to cross-reactivity of the
antibody with neurofilament-L (NF-L). This was confirmed by double-label fluorescent immunohistochemistry and western
blotting with the unpurified GFAP
+1 antibody and an antibody against NF-L. Our data imply that NF-L can accumulate in
some tangle-like structures in Alzheimer brains. More importantly, the purified GFAP
+1 antibody clearly revealed a specific
subtype of astrocytes in the adult human brain. These large astrocytes are present throughout the brain, e.g., along the
subventricular zone, in the hippocampus, in the striatum and in the spinal cord of controls, Alzheimer, and Parkinson
patients. The presence of a specific GFAP-isoform suggests a specialized function of these astrocytes.
Citation: Middeldorp J, van den Berge SA, Aronica E, Speijer D, Hol EM (2009) Specific Human Astrocyte Subtype Revealed by Affinity Purified GFAP
+1 Antibody;
Unpurified Serum Cross-Reacts with Neurofilament-L in Alzheimer. PLoS ONE 4(11): e7663. doi:10.1371/journal.pone.0007663
Editor: Mel B. Feany, Brigham and Women’s Hospital/Harvard Medical School, United States of America
Received August 29, 2009; Accepted October 8, 2009; Published November 4, 2009
Copyright:  2009 Middeldorp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Internationale Stichting Alzheimer Onderzoek (ISAO; 04511; EH) - www.alzheimer.nl/ Hersenstichting Nederland (HsN; 13F05.08; EH) - www.
hersenstichting.nl Internationaal Parkinson Fonds (EH) - www.parkinsonfonds.nl Dorpmans-Wigmans-Stichting (EH) EU FP7 project NeuroGlia (Grant Agreement
Nu 202167; EA) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: e.hol@nin.knaw.nl
Introduction
Glial fibrillary acidic protein (GFAP) belongs to class III of the
intermediate filament (IF) proteins and is used as a specific marker
for astrocytes. Besides expression in astrocytes, GFAP expression
has also been observed in non-CNS cells such as Schwann cells
[1,2], fibroblasts [2] and hepatic stellate cells [3], but also in
degenerating hippocampal neurons in AD and Down syndrome
patients [4,5]. This neuronal expression became apparent upon
studying two novel GFAP splice variants, GFAPDexon6 and
GFAPD164. Translation of these out-of-frame splice variants of
GFAPa, the canonical GFAP isoform, results in two proteins with
the same frameshifted carboxy (C)-terminus, against which we
raised a specific antibody named GFAP
+1. Immunohistochemistry
with this antibody revealed that mainly neurons express GFAP
+1
and only a few astrocytes, contrasting with a commonly used
GFAP antibody that clearly stained many astrocytes and also the
tangles, but much weaker. The neuronal expression was also
obvious when using polyclonal antibodies of Dako, Sigma and
raised by Dahl [5]. These remarkable results initiated us to further
investigate neuronal GFAP expression.
Here we report that although additional GFAP antibodies, with
their epitope mapping at the C-terminus or amino (N)-terminus of
human GFAPa, do stain neuron-like structures, neuronal staining
with the GFAP
+1 antibody disappeared after affinity purification of
the antibody. Mass spectrometry revealed that the neuronal
staining by the GFAP
+1 antibody was caused by a cross-reaction
with neurofilament-L (NF-L). This study shows that some tangle-
like neurons in Alzheimer brains accumulate NF-L. Furthermore,
we could identify a subpopulation of astrocytes in the human brain
by the GFAP
+1 antibody, which became apparent upon affinity
purification.
Materials and Methods
Human Post-Mortem Brain and Spinal Cord Material
Human post-mortem paraffin-embedded and frozen brain
material, and frozen spinal cord samples were obtained from the
Netherlands Brain Bank (NBB), Amsterdam. Spinal cord filaments
were purified as described previously [6]. Frozen spinal cord (S06/
9) used for immunostaining was obtained from the Amsterdam
Medical Center, Amsterdam. More detailed donor information is
presented in table 1. Fetal brain material and that of young control
donors was obtained from the department of Neuropathology of
the Academic Medical Center in Amsterdam.
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+1 Antibody
The GFAP
+1 antibody [5] was affinity-purified by using CnBr-
activated Sepharose 4B beads (GE Healthcare, Fairfield, United
States) [7]. First 1 gram of CnBr-activated Sepharose 4B beads
was incubated in 3.5 ml 1 mM HCl to let them swell. After that,
they were washed twice with acetate buffer (0.1 M sodium acetate,
0.5 M NaCl, pH 4.0). Next, 1 ml of the beads was mixed with
400 mg peptide against which the GFAP
+1 antibody was raised
(EDRGDAGWRG; synthesized by the Netherlands Cancer
Institute batch 6EH1) in 5 ml coupling buffer (0.1 M boric acid
and 0.5 M NaCl pH 8.3). The peptide was coupled to the beads
while mixing head over head for approximately 16 hours at 4uC.
Subsequently, the beads were washed three times with coupling
buffer and incubated with blocking buffer (1 M Glycine, pH 8) for
2 hours at 4uC while rotating head over head. The beads were
then washed twice by alternating ammonium formate buffer
(0.1 M ammonium formate, pH 2.7) and Tris buffer (0.1 M Tris,
0.5 M NaCl, pH 8), and once more with ammonium formate
buffer. After a final wash with PBS (137 mM NaCl, 2.7 mM KCl,
1.8 mM KH2PO4, and 4 mM Na2HPO4, pH 7.4) 1 ml GFAP
+1
antibody with 1 ml PBS was added to the beads in a column and
incubated for 1 hour at room temperature. Flow-through
(aspecific fraction) was stored in a tube and the specific antibodies
were obtained from the column by rinsing it with 4 ml PBS (5
times) and eluting it with 4 ml 0.1 M ammonium formate (6
times). Each elution fraction was immediately neutralized with
3.5 ml 1 M ammonium and stored at 280uC. Western blotting of
the different fractions confirmed that most specific antibodies were
present in the 1
st elution fraction.
Immunohistochemistry
Paraffin sections were deparaffinised and incubated in 0.3%
H2O2 in methanol for 20 min, before preincubation with 10%
normal horse serum (NHS) in phosphate buffer (PB; 0.05 M
Na2HPO4, 0.05 M NaH2PO4?H2O, pH 7.4) + 0.4% Triton X-
100 for 30 min. Next, sections were incubated with primary
antibodies GFAP
+1 (bleeding 150498; 1:1000 [5]), GFAP
+1
purified (bleeding 120598; 1:250), pan-GFAP (Dako; 1:1000),
GFAP C-term (sc-6170, Santa Cruz Biotechnology, Inc.; 1:200)
and GFAP N-term (sc-6171, Santa Cruz Biotechnology, Inc.;
1:200) overnight in PB + 3% NHS + 0.04% Triton X-100. Then,
sections were rinsed with PB three times and incubated with
secondary biotinylated antibodies (Vector Laboratories; 1:400)
in PB + 1% NHS + 0.4% Triton X-100 for 1 hour at room
temperature upon which they were rinsed three times with PB and
incubated with the ABC-complex (1:800 in PB; Vector Labora-
tories) for 30 min. Sections were washed again three times before
incubation with DAB-solution (Sigma; 0.5 mg/ml) for approxi-
mately 10 min. Finally, the sections were washed once in PB, twice
in distilled water, dehydrated in a graded ethanol-xylene series and
embedded in entellan.
For the doublestaining of pan-GFAP and neurofilament, pan-
GFAP (Dako; 1:1000) and pan-neuronal neurofilament (SMI 311,
Covance; 1:1000) antibodies were mixed and incubated together
overnight. The next day, after washing, the sections were
incubated with anti-rabbit-HRP (Dako; 1:500) for 1 hour followed
by washing and incubation with DAB intensified by nickel
ammonium sulphate to get a more black precipitate. After this,
the sections were washed again and incubated with biotinylated
anti-mouse (Vector Laboratories; 1:400) for 1 hour, followed by
30 min incubation with the ABC-complex and DAB as described
before.
Fluorescent staining of GFAP
+1 and NF-L was performed on
frozen hippocampus and spinal cord tissue. Sections were fixed in
4% paraformaldehyde before blocking for 1 hour in 10% NHS in
PB + 0.4% Triton X-100. Subsequently, the sections were
incubated with a polyclonal rabbit antibody against GFAP
+1
Table 1. Detailed donor information.
Donor number Area Sex Age Diagnose Postmortem delay
NBB 96-058 Hippocampus Female 75 Alzheimer’s disease 03:35
NBB 88-073 Hippocampus Male 66 Alzheimer’s disease 03:15
NBB 93-040 Hippocampus Male 83 Alzheimer’s disease 03:15
NBB 01-125 Hippocampus Female 77 Alzheimer’s disease 08:30
NBB 01-119 Hippocampus Male 65 Alzheimer’s disease 08:50
NBB 99-090 Hippocampus Female 82 Alzheimer’s disease 05:20
NBB 95-102 Hippocampus Male 53 Nondemented control 10:00
NBB 06-037 Hippocampus Male 66 Nondemented control 07:45
NBB 00-142 Hippocampus Female 82 Nondemented control 05:30
NBB 01-016 Hippocampus Male 77 Nondemented control 08:25
NBB 01-025 Hippocampus Female 76 Nondemented control 04:05
NBB 05-083 Spinal cord &
Hippocampus
Female 85 Nondemented control 05:00
NBB 01-021 Caudate/putamen Male 82 Nondemented control 07:40
NBB 02-013 Caudate/putamen Female 80 Parkinson’s disease 05:30
NBB 07-006 2 areas of SVZ Male 75 Alzheimer’s disease 05:25
NBB 99-046 Spinal cord Female 89 Nondemented control 05:10
AMC S06-9 Spinal cord Female 72 Nondemented control ,10:00
N.A. Hippocampus Female 39 Nondemented control 07:30
NBB=Netherlands Brain bank; AMC=Amsterdam Medical Center; SVZ=Subventricular zone; N.A.=Not Available.
doi:10.1371/journal.pone.0007663.t001
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ment-L (NF-L; MAB1615, Chemicon; 1:200) diluted in PB + 3%
NHS + 0.4% Triton X-100 overnight at room temperature.
Following, the sections were washed and incubated with secondary
fluorescent antibodies anti-rabbit Alexa FluorH 488 (Molecular
Probes; 1:1400) and anti-mouse Cy3 (Jackson; 1:1400) and nuclear
stain Hoechst 33258 (BioRad; 1:1000). After washing, the sections
were coverslipped with Mowiol (0.1 M Tris pH 8.5, 25% glycerol,
10% w/v Mowiol 4–88 (Sigma)).
Western Blot
Spinal cord filament samples (pellet fraction) were diluted 1:20
with 1x loading buffer (50 mM Tris, 2% SDS, 10% glycerol,
100 mM DTT, 0.005% bromophenol blue). Subsequently, the
samples were run on a 7.5% SDS-PAGE gel and blotted semi-dry
on nitrocellulose. In one experiment, half of the gel was used for
Coomassie staining. Blots were preincubated for 10 min in
Supermix (0.0 M Tris, 0.9% NaCl, 0.25% gelatin and 0.5%
Triton X-100, pH 7.4) before incubation with primary antibodies
GFAP
+1 unpurified (1:500), GFAP
+1 purified (1:250) and NF-L
(1:1000) in Supermix overnight at 4uC. Next, the blots were
washed with TBS-T (TBS; 100 mM Tris-HCl pH 7.4, 150 mM
NaCl, with 0.2% tween-20) and incubated with secondary
antibody anti-rabbit IRDye800 (Rockland Immunochemicals
Inc.; 1:5000) or anti-mouse Cy5 (Jackson; 1:2000) in Supermix
for one hour at RT. After three washes in TBS, bands were
visualized with the Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, USA).
MALDI Analysis
For MALDI analysis, protein-containing gel slices were S-
alkylated (slices were incubated sequentially with 10 mg/50 mM
NH4HCO3 ml DTT (Sigma) for 30 minutes at 55uC and 25 mg/
50 mM NH4HCO3 ml iodoacetamide (Sigma) for 30 minutes at
RT, digested with trypsin (Roche Molecular Biochemicals, sequenc-
ing grade) and extracted according to Shevchenko et al. [8]. After
drying in a vacuum centrifuge, peptides were dissolved in 1% formic
acid and 60% acetonitrile (7 ml). Eluted peptides were mixed 1:1 (v/
v) with a solution containing 52 mM a-cyano-4-hydroxycinnamic
acid (Sigma-Aldrich Chemie BV) in 49% ethanol/49% acetonitrile/
2% TFA and 1 mM ammonium acetate. Prior to dissolving, the a-
cyano-4-hydroxycinnamic acid was washed briefly with chilled
acetone. The mixture was spotted on a MALDI target plate and
allowed to dry at room temperature. Reflectron matrix-assisted laser
desorption ionization time of flight mass spectrometry (MALDI-
TOF MS) spectra were acquired on a Micromass M@LDI (Wy-
thenshawe, UK). The resulting peptide spectra were interpreted
with Micromass proteinprobe software and analyzed with MAS-
COT peptide mass fingerprint software and databases (both
available at http://www.matrixscience.com).
Results
Neuronal-Like GFAP Expression Detected by Distinct
GFAP Antibodies
Neuron-like structures were not only stained by the GFAP
+1
antibody (Fig. 1A, arrows), but also by an antibody against the C-
terminus (Fig. 1B, arrows) and N-terminus (Fig. 1C, arrows) of
GFAPa. In addition, as expected these last two antibodies also
stained the GFAP-IF network of astrocytes in the same area
(Fig. 1B–C, arrowheads). Since the C-terminal GFAP antibody
should not stain the GFAP
+1 protein, as the C-terminus of the
GFAPD164 and GFAPDexon6 isoforms differ completely from the
C-terminus of GFAPa, we concluded that GFAPa is present in the
neuronal structures. These data confirm our earlier results with the
pan-GFAP antibodies from Dako, Sigma and Dahl [5], which also
Figure 1. Neuron-like staining by different GFAP antibodies. Neuron-like structures are stained by the GFAP
+1 (A), GFAP C-terminal (B) and
GFAP N-terminal (C) antibody (arrows). The C-terminal and N-terminal antibodies also stain astrocytes (B–C, arrowheads). Double-labeling of pan-
GFAP (black) and neurofilament (brown) (D–E) shows that neuron-like structures stained by GFAP (E, arrowheads) are surrounded by neurofilament
positive neurons (E, arrow), but do not co-localize. NBB 96-058 (A–C), NBB 88-073 (D–E). Scale bars represent 100 mm (A–C), 200 mm (D), 25 mm (E).
doi:10.1371/journal.pone.0007663.g001
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However, doublestaining with a pan-neuronal neurofilament
antibody (Fig. 1D–E) showed that these GFAP positive neuronal
structures (grey) were different from the neurons stained by the
neurofilament antibody (brown, Fig. 1E, arrow). Although the
neuronal structures were present in the CA1 area of the
hippocampus, no co-localization was seen between pan-GFAP
and neurofilament. This made us question the specificity of the
neuronal GFAP
+1 staining, which appeared to be different from
the pan-GFAP neuron-like staining.
GFAP
+1 Antibody Specificity
A western blot on human spinal cord filaments stained for
GFAP
+1 resulted in two bands; one band migrating at approxi-
mately 70 kDa and one band at approximately 50 kDa (Fig. 2A,
unpur). After affinity purification of the antibody only the 50 kDa
band remained visible (Fig. 1A, pur), which is the expected height
of GFAP
+1 protein as we confirmed by recombinant protein (not
shown). Two bands at the same heights were also visible on the
Coomassie protein gel (not shown) and these bands were isolated
and analyzed by Maldi analysis. Peptide Mass Fingerprinting
analysis of the band migrating at approximately 50 kDa revealed it
to be human GFAP (MOWSE score: 303 with 28 matching
peptides). The band migrating at approximately 70 kDa contained
human Neurofilament Triplet L Protein (NF-L) (MOWSE score:
218 with 22 matching peptides). No peptides possibly derived from
human GFAP could be detected in the upper band. Accordingly,
co-localization of the unpurified GFAP
+1 antibody with human
NF-L was investigated on a western blot with human spinal cord
filaments. The NF-L antibody stained a band at approximately
70 kDa, which co-localized with the band stained by unpurified
GFAP
+1. With the purified GFAP
+1 antibody only the 50 kDa
band was detected, whereas no bands were detected with the pre-
immune serum of the GFAP
+1-immunized rabbit (Fig. 2B). Next,
immunohistochemistry with the purified GFAP
+1 antibody was
performed on human hippocampus slices of Alzheimer donors and
compared to the unpurified antibody. Both neurons and astrocytes
were stained with the unpurified GFAP
+1 antibody (Fig. 2C).
Some of these GFAP
+1 positive neurons clearly co-localized with
NF-L (Fig. 2D), but the astrocytes never co-expressed NF-L
(Fig. 2E). In agreement with the western blot results, only
astrocytes were detected in the sections stained with the purified
antibody (Fig. 2F). Additionally, a western blot on homogenates of
AD and control brains was performed, but no protein bands were
detected after staining with the purified GFAP
+1 antibody, unlike
staining with a pan-GFAP antibody (not shown). Most likely the
number of GFAP
+1 expressing cells in the brain is too low to detect
the level of the GFAP
+1 protein in whole homogenates.
Comparing the sequences of NF-L and GFAP
+1 peptide
revealed some homology in the tail domain of NF-L (Fig. 3),
which might explain the cross-reactivity that occurred. Because
not all GFAP
+1 positive neurons expressed NF-L and vice versa,
we hypothesize that a specific conformational change of NF-L in
tangle-like structures, induced by the AD pathogenesis, exposed
Figure 2. GFAP
+1 cross-reactivity with neurofilament-L is removed by affinity purification. A Western blot on human spinal cord
filaments revealed two bands (,50 kDa and ,70 kDa) when stained with the unpurified GFAP
+1 antibody (A, unpur). After affinity purification of the
antibody only the lower band was left (A, pur). On a western blot that was double-stained for different GFAP
+1 antisera (green) and NF-L (red), the
70 kDa unpurified GFAP
+1 band showed co-localization with NF-L (B, up, yellow band). This was gone with the purified antibody, which only stained
one GFAP
+1 band at 50 kDa (B, pur, green band). With the pre-immune serum of the GFAP
+1 immunized rabbit, no staining was detected (B, pi). The
original unpurified GFAP
+1 antibody stained both neurons and astrocytes in the hippocampus of an AD brain (C, NBB 93-040). These GFAP
+1 (green)
neurons often co-localized with NF-L (red) (D, NBB 01-125), but the astrocytes did not (E, NBB 01-119). The purified GFAP
+1 antibody only stained a
subpopulation of astrocytes (F, NBB 95-102). Scale bars represent 100 mm (C, F), 50 mm (D–E).
doi:10.1371/journal.pone.0007663.g002
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+1
antiserum.
Purified GFAP
+1 Identifies a Specific Subpopulation of
Astrocytes in the Adult Human CNS
During development (Fig. 4A) and in the hippocampus of
healthy young adults (,50 years), no GFAP
+1 expression was
detected with the purified GFAP
+1 antibody either in the dentate
gyrus/hilus region (Fig. 4B) or in the CA areas (Fig. 4C–D).
Immunostaining with the purified GFAP
+1 antibody revealed
conspicuous astrocytes in numerous areas of the CNS in older
control donors (.50 years) or donors with neurodegenerative
diseases. In addition to the hippocampus of Alzheimer (n=6) and
control brains (n=6), GFAP
+1 positive astrocytes were found in
the striatum (caudate/putamen) of control and Parkinson brains
(Fig. 4E–F). Furthermore, GFAP
+1 positive astrocytes were found
in different areas aligning the subventricular zone, e.g. beneath the
cingulated gyrus and in the most posterior part of the lateral
ventricle. In these areas cells were found both in the subventricular
zone (Fig. 4G) as in more superficial layers (Fig. 4H). Fluorescent
immunostaining of transverse (Fig. 4I) and longitudinal (Fig. 4J)
sections of the human spinal cord showed a relatively large
number of GFAP
+1 positive astrocytes. Most intense staining was
found near the meninges (Fig. 4I, arrowheads), in the anterior
horn (Fig. 4I, arrow) and in the grey commisure around the central
canal (Fig. 4I, asterix). Since the investigated brain areas are
known to be full of GFAP positive astrocytes throughout the area,
clearly GFAP
+1 is only expressed in a specific subpopulation of
astrocytes. Besides GFAP
+1 expression, this subpopulation of
astrocytes is characterized by long processes which often contact
blood vessels (Fig. 4E–F, arrows) and their morphology resembles
reactive astrocytes in that sense that GFAP
+1 astrocytes are larger
in size compared to normal resting astrocytes, however the
extensions of the GFAP
+1 astrocytes are smaller in diameter.
Nevertheless, in areas that are full of reactive astrocytes, as
indicated by immunostaining with a pan-GFAP antibody (Fig. 4K–
K’), often no GFAP
+1 staining can be detected (L).
Discussion
In this study we showed that GFAP
+1 is not expressed in
neurons as was previously reported [5]. The neuronal immuno-
reactivity appeared to be due to cross-reactivity of the antibody
with NF-L, which we uncovered by peptide mass fingerprinting.
However, GFAP
+1 is expressed in a specific subpopulation of
astrocytes throughout the brain as revealed by the affinity purified
GFAP
+1 antibody.
How immunization with the GFAP
+1 peptide exactly led to the
production of NF-L recognizing antibodies is not known. The
homology of the GFAP
+1 peptide with 4 amino acids in the tail
domain of NF-L (Fig. 3) could be an explanation. Furthermore,
the issue why only neurons in AD were labeled by the unpurified
GFAP
+1 antibody for NF-L remains unexplained. Perhaps, the
antiserum only detects the monomeric form of NF-L, as was
shown for the 70 kDa band on the western blot (Fig. 2B). This
form has been shown to accumulate in hippocampal neurons of
AD brains [9]. Most neurons with NF-L accumulation resembled
intact neurons, whereas only little NF-L immunoreactivity was
found in tangles. This could also explain why many GFAP
+1
positive neurons were found to have visible nuclei [5].
The affinity purified GFAP
+1 antibody revealed a strong and
specific immunolabeling of a subpopulation of astrocytes in the
hippocampus of Alzheimer donors, and did not label neurons at
all. However, neuron-like structures were still labeled by several
other GFAP antibodies. In an earlier study we have described that
three other pan-GFAP antibodies clearly labeled neuron-like
structures [5], but we show in this study that these were not
neurofilament positive. These GFAP immunopositive neuron-like
structures were also distinct from the neurons that were labeled
with the unpurified GFAP
+1 antiserum. The neuron-like structures
were less intensely labeled with the different GFAP antibodies used
in our earlier study and with the novel GFAP antibodies we used
in this study, that are directed against the C-terminus or N-
terminus of human GFAPa. We suggest, as others have done
before, that the GFAP positive neuron-like structures are ghost
tangles, which are neurofibrillary tangles (NFTs) emerging into
extracellular space that are associated with prominent astrocytic
invasion including glial filaments [10,11]. In a study by Ikeda et al.,
these ghost tangles were shown to be GFAP positive and the
GFAP staining that they show strongly resembles the GFAP
positive neuron-like structures that we showed in our study [10].
Interestingly, the specific GFAP
+1 immunolabeling in astrocytes
remained present after affinity purification. This expression
pattern did not get much attention before since GFAP expression
in astrocytes is common, unlike neuronal expression. However, the
purified GFAP
+1 antibody intensely stained a small number of
large astrocytes with several long processes often directed towards
blood vessels. This subpopulation of astrocytes was found in the
hippocampus, the striatum, the spinal cord and in several areas
aligning the subventricular zone in brains of elderly non-demented
controls, Alzheimer and Parkinson patients. GFAP
+1 expression
was not present during brain development or in brains of young
controls. This indicates that GFAP
+1, in addition to the previously
described GFAP isoform GFAPd in subpial and subventricular
zone astrocytes [12], marks a specific subpopulation of astrocytes.
GFAP
+1 immunostaining of gliotic brain areas revealed that this
GFAP
+1 expressing subpopulation is distinct from the population
of reactive astrocytes. More elaborate characterization of these
astrocytes and the possible role of the GFAP
+1 protein therein will
be further investigated. In light of the increasing interest in the
Figure 3. Sequence homology between neurofilament-L and the GFAP
+1 antibody epitope. Some homology (green and yellow
highlights) was found between the tail domain of NF-L (red letters) and the GFAP
+1 antibody epitope (blue letters).
doi:10.1371/journal.pone.0007663.g003
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+1 expressing astrocytes in different areas of the human CNS. No GFAP
+1 expression is detected in the developing
hippocampus of a 16 week old human fetus (A), or in the hippocampus of a 39 year old healthy female, neither in the dentate gyrus/hilus (B) nor in
CA1 (C) or CA3 (D) regions. The purified GFAP
+1 antibody clearly stained a subpopulation of astrocytes throughout the brain, e.g. in the caudate/
putamen (E–F), along the subventricular zone of the lateral ventricle beneath the cingulate gyrus (G) and in the most posterior part of the lateral
ventricle (H). Often cells were found contacting blood vessels (E–F, arrows). A relatively large number of GFAP
+1 expressing cells was detected in the
human spinal cord (I–J). Most expression was found near the meninges (arrowheads), in the anterior horn (arrow) and in the grey commissure around
the central canal (asterix) as shown in half of a transverse section (I). A GFAP
+1 expressing cell and surrounding processes are shown in more detail in
a longitudinal section (J). Pan-GFAP staining reveals many reactive astrocytes in the hippocampus (K), which clearly show intense GFAP expression
and hypertrophic cell bodies in a magnified image of the squared area (K’). GFAP
+1 staining in the same area of an adjacent section shows no staining
at all (L), indicating GFAP
+1 does not generally mark reactive astrocytes. NBB 01-021 (E), NBB 02-013 (F), NBB 07-006 (G-H), AMC 06/9 (I–J), NBB 05-083
(K–L). Scale bars represent 500 mm (A–B, K–L), 200 mm (C–D),100 mm (E, G–H, J, 50 mm (B, K’), 1 mm (I).
doi:10.1371/journal.pone.0007663.g004
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antibodies might be of value to identify specific subtypes.
Furthermore, the different GFAP-IF networks might be instru-
mental in revealing the diverse functions of specific astrocyte
subtypes.
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